Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | GGT1 | P19440 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4783065 | 1.00 | FOLH1 (0.45) | FOLH1GSRGABRR1CPB2SLC6A5 | |
| SCHEMBL4951252 | 0.94 | GSR (0.52) | FOLH1GSRGABRR1CPB2SLC6A5 | |
| SCHEMBL7027613 | 0.86 | FOLH1 (0.46) | FOLH1GSRGABRR1CPB2SLC6A5 | |
| SCHEMBL7027611 | 0.86 | FOLH1 (0.46) | FOLH1GSRGABRR1CPB2SLC6A5 | |
| SCHEMBL3725106 | 0.86 | FOLH1 (0.46) | FOLH1GSRGABRR1CPB2SLC6A5 | |
| SCHEMBL5869685 | 0.85 | FOLH1 (0.45) | FOLH1GSRGABRR1CPB2SLC6A5 | |
| SCHEMBL8254457 | 0.85 | FOLH1 (0.45) | FOLH1GSRGABRR1CPB2SLC6A5 | |
| SCHEMBL1413149 | 0.81 | FOLH1 (0.53) | FOLH1GSRGABRR1CPB2SLC6A5 | |
| SCHEMBL209237 | 0.81 | FOLH1 (0.53) | FOLH1GSRGABRR1CPB2SLC6A5 | |
| SCHEMBL3727817 | 0.81 | FOLH1 (0.53) | FOLH1GSRGABRR1CPB2SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442788-B2 | Antisense molecules and method of controlling expression of gene function by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2008-10-28 | — | — | US | claimed |
| US-6872809-B2 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2005-03-29 | — | — | US | claimed |
| US-20030208050-A1 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-11-06 | — | — | US | claimed |
| US-20030162739-A1 | Antisense molecules and method of controlling expression of gene function by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-08-28 | — | — | US | claimed |
| EP-1295892-A1 | ANTISENSE MOLECULES AND METHOD OF CONTROLLING EXPRESSION OF GENE FUNCTION BY USING THE SAME | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | claimed |
| EP-1295891-A1 | NUCLEOSIDE DERIVATIVES | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | claimed |
| US-7442788-B2 | Antisense molecules and method of controlling expression of gene function by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20080038783-A1 | Compositions and Methods Pertaining to Guanylation of PNA Oligomers | APPLERA CORPORATION (US) | 2008-02-14 | — | — | US | disclosed |
| WO-2008003079-A1 | COMPOSITIONS AND METHODS PERTAINING TO GUANYLATION OF PNA OLIGOMERS | APPLERA CORPORATION (US) | 2008-01-03 | — | — | WO | disclosed |
| US-6872809-B2 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2005-03-29 | — | — | US | disclosed |
| US-6872809-B2 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2005-03-29 | — | — | US | disclosed |
| EP-1295891-A4 | NUCLEOSIDE DERIVATIVES | JAPAN SCIENCE & TECH CORP (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-20030208050-A1 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-11-06 | — | — | US | disclosed |
| US-20030208050-A1 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-11-06 | — | — | US | disclosed |
| US-20030162739-A1 | Antisense molecules and method of controlling expression of gene function by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1295892-A1 | ANTISENSE MOLECULES AND METHOD OF CONTROLLING EXPRESSION OF GENE FUNCTION BY USING THE SAME | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | disclosed |
| EP-1295891-A1 | NUCLEOSIDE DERIVATIVES | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | disclosed |
| EP-1295891-A1 | NUCLEOSIDE DERIVATIVES | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001096355-A1 | NUCLEOSIDE DERIVATIVES | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038783-A1 | Compositions and Methods Pertaining to Guanylation of PNA Oligomers | RNMT, RNGTT, UNG | FOLH1 1786/4885GSR 1057/4885GABRR1 2071/4885 |
| US-20030162739-A1 | Antisense molecules and method of controlling expression of gene function by using the same | RNGTT, RNMT, UPF1 | FOLH1 789/4885GSR 3049/4885GABRR1 1229/4885 |
| US-20030208050-A1 | Nucleoside derivatives | RIMKLA, MTHFD1, AADAT | FOLH1 67/4885GSR 1541/4885GABRR1 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.